CY1123861T1 - Θεραπευτικη αντιμετωπιση εξαψεων και οστικης απωλειας, επαγομενων απο θεραπεια στερησης ανδρογονων, με χρηση cis-κλομιφαινης - Google Patents
Θεραπευτικη αντιμετωπιση εξαψεων και οστικης απωλειας, επαγομενων απο θεραπεια στερησης ανδρογονων, με χρηση cis-κλομιφαινηςInfo
- Publication number
- CY1123861T1 CY1123861T1 CY20201101032T CY201101032T CY1123861T1 CY 1123861 T1 CY1123861 T1 CY 1123861T1 CY 20201101032 T CY20201101032 T CY 20201101032T CY 201101032 T CY201101032 T CY 201101032T CY 1123861 T1 CY1123861 T1 CY 1123861T1
- Authority
- CY
- Cyprus
- Prior art keywords
- androgen deprivation
- cis
- bmd
- loss
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Αυτή η εφεύρεση παρέχει: 1) μία μέθοδο θεραπευτικής αντιμετώπισης οστεοπόρωσης, οστικών καταγμάτων, απώλειας οστικής πυκνότητας (BMD), ή/και εξάψεων επαγόμενων από στέρηση ανδρογόνων, σε άρρεν υποκείμενο το οποίο πάσχει από καρκίνο του προστάτη 2) μία μέθοδο πρόληψης οστεοπόρωσης, οστικών καταγμάτων, απώλειας οστικής πυκνότητας (BMD), ή/και εξάψεων επαγόμενων από στέρηση ανδρογόνων, σε άρρεν υποκείμενο το οποίο πάσχει από καρκίνο του προστάτη μία μέθοδο καταστολής ή αναστολής οστεοπόρωσης, οστικών καταγμάτων, απώλειας οστικής πυκνότητας (BMD), ή/και εξάψεων επαγόμενων από στέρηση ανδρογόνων, σε άρρεν υποκείμενο το οποίο πάσχει από καρκίνο του προστάτη και 4) μία μέθοδο μείωσης του κινδύνου ανάπτυξης οστεοπόρωσης, οστικών καταγμάτων, απώλειας οστικής πυκνότητας (BMD), ή/και εξάψεων επαγόμενων από στέρηση ανδρογόνων, σε άρρεν υποκείμενο το οποίο πάσχει από καρκίνο του προστάτη, με χορήγηση στο υποκείμενο μίας φαρμακευτικής σύνθεσης η οποία συνίσταται σε cis-κλομιφαίνη ή ένα φαρμακευτικώς αποδεκτό άλας αυτής.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462028540P | 2014-07-24 | 2014-07-24 | |
PCT/US2015/041761 WO2016014812A1 (en) | 2014-07-24 | 2015-07-23 | Treating androgen deprivation therapy induced hot flashes and bone loss using cis-clomiphene |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123861T1 true CY1123861T1 (el) | 2022-03-24 |
Family
ID=55163768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201101032T CY1123861T1 (el) | 2014-07-24 | 2020-11-02 | Θεραπευτικη αντιμετωπιση εξαψεων και οστικης απωλειας, επαγομενων απο θεραπεια στερησης ανδρογονων, με χρηση cis-κλομιφαινης |
Country Status (19)
Country | Link |
---|---|
US (3) | US9913815B2 (el) |
EP (2) | EP3171866B1 (el) |
JP (1) | JP6743001B2 (el) |
KR (2) | KR20170040797A (el) |
CN (2) | CN111346076A (el) |
AU (1) | AU2015292519B2 (el) |
CY (1) | CY1123861T1 (el) |
DK (1) | DK3171866T3 (el) |
ES (1) | ES2828305T3 (el) |
HR (1) | HRP20201726T1 (el) |
HU (1) | HUE051442T2 (el) |
IL (2) | IL249989B (el) |
LT (1) | LT3171866T (el) |
MX (1) | MX2017000886A (el) |
PL (1) | PL3171866T3 (el) |
PT (1) | PT3171866T (el) |
RU (2) | RU2725086C2 (el) |
UA (1) | UA121971C2 (el) |
WO (1) | WO2016014812A1 (el) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3171866B1 (en) * | 2014-07-24 | 2020-08-19 | Aspen Park Pharmaceuticals, Inc. | Treating androgen deprivation therapy induced hot flashes and bone loss using cis-clomiphene |
FR3082842A1 (fr) * | 2018-06-21 | 2019-12-27 | Veru Inc. | Polymorphe de cis-clomiphene (zuclomiphene) et procedes d'utilisation de celui-ci |
CA3098725A1 (en) | 2019-11-14 | 2021-05-14 | Apotex Inc. | Zuclpomiphene salts and crystalline forms thereof |
CA3098552A1 (en) | 2019-11-14 | 2021-05-14 | Apotex Inc. | Processes for the preparation of zuclomiphene and intermediates thereof |
CA3105944A1 (en) | 2020-01-22 | 2021-07-22 | Apotex Inc. | Crystalline forms of zuclomiphene citrate |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT951631B (it) | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
US20040214898A1 (en) | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
AU2002356928B2 (en) * | 2001-11-29 | 2008-04-17 | Gtx Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
US6762524B2 (en) * | 2002-08-01 | 2004-07-13 | Albert Six | Magnetic drive system for a vehicle differential |
CN101151043B (zh) * | 2004-12-21 | 2013-09-04 | 南卡罗来纳州医科大学研究发展基金会 | 促进伤口愈合和组织再生的组合物和方法 |
US8637706B2 (en) * | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
US20090215733A1 (en) * | 2008-02-26 | 2009-08-27 | Michael Charles Scally | Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake |
EP3171866B1 (en) * | 2014-07-24 | 2020-08-19 | Aspen Park Pharmaceuticals, Inc. | Treating androgen deprivation therapy induced hot flashes and bone loss using cis-clomiphene |
-
2015
- 2015-07-23 EP EP15824708.0A patent/EP3171866B1/en active Active
- 2015-07-23 LT LTEP15824708.0T patent/LT3171866T/lt unknown
- 2015-07-23 US US15/327,726 patent/US9913815B2/en active Active
- 2015-07-23 JP JP2017525313A patent/JP6743001B2/ja active Active
- 2015-07-23 WO PCT/US2015/041761 patent/WO2016014812A1/en active Application Filing
- 2015-07-23 MX MX2017000886A patent/MX2017000886A/es unknown
- 2015-07-23 ES ES15824708T patent/ES2828305T3/es active Active
- 2015-07-23 UA UAA201700302A patent/UA121971C2/uk unknown
- 2015-07-23 EP EP20190827.4A patent/EP3769756A1/en active Pending
- 2015-07-23 KR KR1020177005185A patent/KR20170040797A/ko not_active IP Right Cessation
- 2015-07-23 RU RU2017105837A patent/RU2725086C2/ru active
- 2015-07-23 PT PT158247080T patent/PT3171866T/pt unknown
- 2015-07-23 AU AU2015292519A patent/AU2015292519B2/en active Active
- 2015-07-23 CN CN202010205589.4A patent/CN111346076A/zh active Pending
- 2015-07-23 DK DK15824708.0T patent/DK3171866T3/da active
- 2015-07-23 CN CN201580040181.3A patent/CN107072969B/zh active Active
- 2015-07-23 HU HUE15824708A patent/HUE051442T2/hu unknown
- 2015-07-23 PL PL15824708T patent/PL3171866T3/pl unknown
- 2015-07-23 RU RU2020120156A patent/RU2020120156A/ru unknown
- 2015-07-23 KR KR1020227044756A patent/KR20230005415A/ko not_active Application Discontinuation
-
2017
- 2017-01-09 IL IL249989A patent/IL249989B/en unknown
-
2018
- 2018-01-25 US US15/879,861 patent/US10463635B2/en active Active
-
2019
- 2019-09-24 US US16/580,198 patent/US10758500B2/en active Active
-
2020
- 2020-10-26 HR HRP20201726TT patent/HRP20201726T1/hr unknown
- 2020-11-02 CY CY20201101032T patent/CY1123861T1/el unknown
-
2022
- 2022-01-20 IL IL290004A patent/IL290004A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123861T1 (el) | Θεραπευτικη αντιμετωπιση εξαψεων και οστικης απωλειας, επαγομενων απο θεραπεια στερησης ανδρογονων, με χρηση cis-κλομιφαινης | |
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
BR112018013731A2 (pt) | combinações anti-egfr para o tratamento de tumores | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
EA201692472A1 (ru) | Соединения для лечения рака мозга | |
EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
MX2021006734A (es) | Metodo para tratar el cancer. | |
MX2016014253A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
BR112018013733A2 (pt) | combinações anti-cd20 para o tratamento de tumores a | |
EA201692513A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
EA201692470A1 (ru) | Фармацевтические комбинации | |
MX2017009246A (es) | Farmaco de combinacion. | |
MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
IL279591A (en) | Cancer treatment methods using combination therapy | |
EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
MX2020006224A (es) | Metodos y terapia combinada para el tratamiento del cancer. | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
EA201790604A1 (ru) | Ингибиторы гистондеметилазы | |
EA201892311A1 (ru) | Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга |